97 related articles for article (PubMed ID: 6288064)
21. Circadian rhythms in the urinary excretion of cyclic 3',5'-adenosine monophosphate (cyclic AMP) and cyclic 3',5'-guanosine monophosphate (cyclic GMP) in human subjects.
Kopp L; Lin T; Tucci JR
J Clin Endocrinol Metab; 1977 Apr; 44(4):673-80. PubMed ID: 191467
[TBL] [Abstract][Full Text] [Related]
22. Treatment for recurrent ovarian cancer. A report of 2 cases.
Maxwell AM; Jordaan JP
S Afr Med J; 1987 Feb; 71(3):180. PubMed ID: 3810370
[TBL] [Abstract][Full Text] [Related]
23. Urinary excretion of cyclic-AMP and cyclic-GMP in allergic children throughout seven months of hyposensitization treatment.
Castellote MC; Muñoz Lopez F; Barbera G; Torralba A
Ann Allergy; 1981 May; 46(5):281-3. PubMed ID: 6263134
[TBL] [Abstract][Full Text] [Related]
24. Urinary excretion of prostacyclin and thromboxane degradation products in patients with ovarian malignancy: effect of cytostatic treatment.
Aitokallio-Tallberg A; Viinikka L; Ylikorkala O
Br J Cancer; 1989 Nov; 60(5):785-8. PubMed ID: 2803956
[TBL] [Abstract][Full Text] [Related]
25. [Cyclophosphamide with dextran as a carrier in the therapy of ovarian neoplasms. Clinical trial].
Cadenelli GP; Spreafichi F
Quad Clin Ostet Ginecol; 1966 Oct; 21(10):686-99. PubMed ID: 5996153
[No Abstract] [Full Text] [Related]
26. [Early results of polychemotherapy in advanced ovarian tumors].
Rózewicki S; Rzepka I; Górski H
Ginekol Pol; 1979 Nov; 50(11):953-6. PubMed ID: 544354
[No Abstract] [Full Text] [Related]
27. [Cyclophosphamide with dextran as a carrier in the therapy of ovarian neoplasms. Clinical trial].
Cadenelli GP; Spreafichi F
Quad Clin Ostet Ginecol; 1966 Oct; 21(10):686-9. PubMed ID: 5996154
[No Abstract] [Full Text] [Related]
28. Tumour cell activity markers in epithelial ovarian cancer: are biochemical and cytometric indices complementary?
Redman CW; Finn C; Ward K; Kelly K; Buxton EJ; Varma R; Shortland-Webb W; Luesley DM
Br J Cancer; 1990 May; 61(5):755-8. PubMed ID: 2159769
[TBL] [Abstract][Full Text] [Related]
29. Treatment by combined chemotherapy for recurrent ovarian cancer.
Shershah S
J Pak Med Assoc; 1985 Nov; 35(11):341-3. PubMed ID: 3935821
[No Abstract] [Full Text] [Related]
30. Treatment and immunodiagnosis of advanced ovarian adenocarcinoma: a preliminary report.
Piver MS; Barlow JJ; Bhattacharya M
Cancer Treat Rep; 1979 Feb; 63(2):265-7. PubMed ID: 376133
[TBL] [Abstract][Full Text] [Related]
31. Plasma and urine cyclic nucleotide levels in malignant disease and cirrhosis of the liver.
Wood PJ; Ross G; Smith CL
J Clin Pathol; 1979 Oct; 32(10):998-1002. PubMed ID: 230205
[TBL] [Abstract][Full Text] [Related]
32. Urinary cyclic nucleotide levels in patients with hyper- and hypothyroidism.
Tucci JR; Kopp L
J Clin Endocrinol Metab; 1976 Dec; 43(6):1323-9. PubMed ID: 187614
[TBL] [Abstract][Full Text] [Related]
33. [The value of etoposide (VP-16) in the therapy of refractory ovarian cancer].
Marth C; Pointner E; Zeimet AG; Abfalter E; Koza A; Windbichler G; Hetzel H; Dapunt O
Geburtshilfe Frauenheilkd; 1993 May; 53(5):303-7. PubMed ID: 8514100
[TBL] [Abstract][Full Text] [Related]
34. Urinary excretion of adenosine 3',5'-monophosphate and guanosine 3',5'-monophosphate in normal children and those with cystic fibrosis.
Murad F; Moss WW; Johanson J; Selden RF
J Clin Endocrinol Metab; 1975 Apr; 40(4):552-9. PubMed ID: 165210
[TBL] [Abstract][Full Text] [Related]
35. [The value of determination of urine cAMP and cGMP in the diagnosis and predicting the therapeutic effect of malignant ovarian tumors].
Wu XH; Zhang JG
Zhonghua Fu Chan Ke Za Zhi; 1991 May; 26(3):162-5, 188. PubMed ID: 1651834
[TBL] [Abstract][Full Text] [Related]
36. Treatment of 126 cases of advanced ovarian carcinoma with cyclophosphamide.
Beck RE; Boyes DA
Can Med Assoc J; 1968 Mar; 98(11):539-41. PubMed ID: 5647240
[No Abstract] [Full Text] [Related]
37. [Metastatic brain tumor after chemotherapy of ovarian cancer].
Fukuda K; Chen JT; Fujimoto I; Yamauchi K; Hasumi K; Masubuchi K; Sakamoto A
Gan No Rinsho; 1987 Jan; 33(1):115-8. PubMed ID: 3102810
[TBL] [Abstract][Full Text] [Related]
38. Phase II study of spirogermanium in advanced ovarian malignancy.
Tropé C; Mattsson W; Gynning I; Johnsson JE; Sigurdsson K; Orbert B
Cancer Treat Rep; 1981; 65(1-2):119-20. PubMed ID: 6261944
[TBL] [Abstract][Full Text] [Related]
39. Immunochemical demonstration of an ovarian cancer-associated urinary peptide.
Stenman UH; Huhtala ML; Koistinen R; Seppälä M
Int J Cancer; 1982 Jul; 30(1):53-7. PubMed ID: 6811446
[TBL] [Abstract][Full Text] [Related]
40. [Treatment of advanced ovarian cancer with cis-dichlorodiammine platinum (CDDP) as single agent or cddp in combination with adriamycin (ADM)].
Nishimura H; Yamada T; Hagio Y; Inoue T; Tsunawaki A; Yakushiji M; Kato T
Gan To Kagaku Ryoho; 1983 Apr; 10(4 Pt 1):938-43. PubMed ID: 6683483
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
